GlassScriptPhysician profile
Joseph A Horstman
NPI 1720198195
$5,752.44
in general payments reported to CMS, 2019-2025
24 companies · $730 in 2025
The $730 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $349 · 2021: $862 · 2022: $1,002 · 2023: $1,036 · 2024: $1,046 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.15 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,409.39 | 2019-2025 | |
| Pfizer INC. | $899.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $655.58 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $477.20 | 2022-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $453.47 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.74 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $309.74 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $255.59 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $186.05 | 2022-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $117.78 | 2022-2023 | Mitraclip |
| Heartflow, INC. | $100.22 | 2021 | |
| Novo Nordisk INC | $98.97 | 2024-2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $85.21 | 2021 | |
| Scpharmaceuticals INC. | $45.10 | 2024 | |
| Philips North America LLC | $44.45 | 2024 | (Ck4) Mcot |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $36.75 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $35.32 | 2025 | Arexvy, Shingrix |
| Kestra Medical Technology Services, INC. | $33.47 | 2024 | Assure Wcd |
| Medtronic, INC. | $33.02 | 2022-2025 | Symplicity G3 |
| Esperion Therapeutics, INC. | $19.80 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $18.30 | 2023 | Arcalyst |
| Vifor Pharma, INC. | $16.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.96 | 2019 | |
| Irhythm Technologies, INC. | $13.27 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Horstman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.